Advertisement

Polatuzumab Vedotin-piiq Plus R-CHP vs R-CHOP in Previously Untreated DLBCL: POLARIX Trial
Posted: 03/03/2022 | By: Matthew Stenger

Question 1 of 5

What kind of agent is polatuzumab vedotin-piiq?

Choose 1

A
A bispecific antibody
B
An immune checkpoint inhibitor
C
An antibody-drug conjugate targeting CD38
D
An antibody-drug conjugate targeting CD79b

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage